Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. Janjigian YY et al. New England Journal of Medicine 2025. PMID: 40454643
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Janjigian YY et al. Journal of Clinical Oncology 2018. PMID: 30110194
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Janjigian YY et al. Lancet 2021. PMID: 34102137
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Shitara K… Janjigian YY. Nature 2022 PMID: 35322232
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Janjigian YY et al Journal of Clinical Oncology 2024. PMID: 38382001
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Shitara K, Janjigian YY et al Nature Medicine 2025. PMID: 40055521
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Janjigian YY, Maron SB et al Lancet Oncology 2020. PMID: 32437664
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Janjigian YY et al. Nature 2021.PMID: 34912120
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Janjigian YY et al Lancet 2023. PMID: 37871604
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. Maron SB…Janjigian YY. Clinical Cancer Research 2023. PMID: 37406106
Pembrolizumab in HER2-Positive Gastric Cancer. Janjigian YY et al New England Journal of Medicine 2024. PMID: 39282917